| Literature DB >> 23840917 |
Sunil Joshi1, Ammon B Peck, Saeed R Khan.
Abstract
A major role of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes is to catalyze the production of superoxides and other reactive oxygen species (ROS). These ROS, in turn, play a key role as messengers in cell signal transduction and cell cycling, but when they are produced in excess they can lead to oxidative stress (OS). Oxidative stress in the kidneys is now considered a major cause of renal injury and inflammation, giving rise to a variety of pathological disorders. In this review, we discuss the putative role of oxalate in producing oxidative stress via the production of reactive oxygen species by isoforms of NADPH oxidases expressed in different cellular locations of the kidneys. Most renal cells produce ROS, and recent data indicate a direct correlation between upregulated gene expressions of NADPH oxidase, ROS, and inflammation. Renal tissue expression of multiple NADPH oxidase isoforms most likely will impact the future use of different antioxidants and NADPH oxidase inhibitors to minimize OS and renal tissue injury in hyperoxaluria-induced kidney stone disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23840917 PMCID: PMC3690252 DOI: 10.1155/2013/462361
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Production of ROS and different reactions. ROS with 1 free electron are shown in red and 2 free electrons are shown in blue. ROS, when produced in excess, cause damage to different components of the cell. Excess production of hydrogen peroxide (H2O2) and peroxynitrite (ONOO−) leads to the production of singlet oxygen (1O2). The other radicals shown in the figure are superoxide (•O2 −), nitric oxide (•NO), nitrogen dioxide (•NO2), hydroxyl radical (•OH), glutathione (GSH), glutathione disulphide (GSSG), thiocyanate (SCN−), hypothiocyanous acid (HOSCN), hypochlorous acid (HOCl), and chroramine (R-NHCl). Figure modified from [1, 46].
Figure 2Seven different NOX isoforms-NADPH oxidase complexes. NOX isoform expression is relatively regulated at different transcriptional, post-transcriptional and translational levels under certain pathophysiological conditions. Most of the NOX isoforms have structural similarities to NOX2, with maximum in NOX3. NOX4 is most abundant in the kidneys in various kinds of cells. NOX4 is known to be constitutively active and do not require any subunits. NOX5 is directly activated by calcium. The core subunits of all the complexes (NOX1-NOX5, DUOX1/DUOX2) are shown in blue; their membrane bound subunits (p22phox, DUOXA1 and DUOXA2) are shown in green; the cytosolic subunits which acts as organizers (p40phox, NOXO1 and p47phox) are shown in red; activator subunits of NADPH oxidase complexes present in the cytosol (p67phox and NOXA1) are shown in orange; small GTPases (RAC1 and RAC2) are shown in grey; EF hand motifs are shown in yellow which bind with calcium to regulate the activity of NOX5, DUOX1 and DUOX2 (see text for details).
Figure 3Different isoforms of NADPH oxidase complex present in different parts of the kidneys. The Nox isoforms expressed in the cortex and medulla as shown in the nephron and different cellular populations in the glomerulus (see text for details).
Inhibitors of NADPH oxidase.
| Name | Mode of action | Pharmacological effects | References |
|---|---|---|---|
| Apocynin | NADPH oxidase complex assembly inhibitor: inhibits binding of p47phox with membrane bound p22phox | Scavenger of H2O2 | [ |
| DPI | Inhibitor of flavoprotein, takes electrons from FAD and prevents electron flow through the flavocytochrome channel | Inhibitor of NADH-ubiquinone oxidoreductase, NADH dehydrogenase, xanthine oxidase, cytochrome p450 oxidoreductase, NOS, and bacterial nicotine oxidase | [ |
| AEBSF | Inhibits association of NOX2 subunit with p47phox. Prevents binding of p47phox and p67phox with cytochrome b559 | Irreversible serine protease inhibitor | [ |
| Plumbagin | Inhibits O2 −• production in various cell lines expressing NOX4 oxidase; unknown mechanism | Naphthoquinone structure may confer ROS-scavenging effects | [ |
| PR-39 | Inhibits p47phox from binding to p22phox subunit by cohering to SH3 domains of p47pphox | Non selective for NADPH oxidase | [ |
| S17834 | Flavonoid derivative proposed to directly inhibit NADPH oxidase activity, although the mechanism is undefined | None | [ |
| VAS2870 | Undefined mechanism: inhibits NADPH oxidase activity in NOX2 oxidase-containing HL-60 cell line and in vascular endothelial cells containing NOX2 and NOX4 oxidases; does not scavenge O2 −• | None | [ |
| Gp91dstat | Oxidase assembly inhibitor: inhibits association of Nox2 with p47phox. Does not scavenge superoxide generated by cell-free systems | None | [ |
| Statins | Decrease superoxide production by inhibiting synthesis of farnesylpyrophosphate and geranylgeranylpyrophosphate which are crucial for membrane attachment of Rac and NADPH oxidase assembly. May also decrease p22phox and Nox1 expression. Likely to influence Nox1 and Nox2 activities | HMG-CoA reductase inhibitor. Decreases AT1 receptor expression; increases eNOS expression, most effective for treating cardiovascular disease with questionable benefit in those without previous CVD but with elevated cholesterol levels | [ |
| AT1 receptor antagonists | Decrease Ang II-dependent activation of NADPH oxidase via AT1 receptors. Unlikely to display Nox selectivity as Ang II stimulates Nox1 and Nox4 oxidases | None. Controlling high blood pressure | [ |
| Nebivolol | Inhibits membrane association and also interaction of p67phox and Rac and decreases oxidase expression. Inhibits Nox1-dependent superoxide production |
| [ |
| Gliotoxin | A fungal metabolite, thiol-modifying toxin thought to inhibit phosphorylation of p47phox by preventing PKC colocalization with p47phox. Also, inhibits electron transport through the flavocytochrome before oxidase activation. Low potency for blocking Nox4 | Stimulation of cGMP release. Cytoskeletal reorganization. Disrupts the mitochondrial membrane potential, possesses immunosuppressive properties, anti-inflammatory activity. | [ |
| Clostridium difficile toxin B | Glycosylation of threonine-35 on Rac, which modifies GTPases activity | Likely to inhibit all Rac-dependent protein activity. High toxicity, vascular permeability and inflammation | [ |
| Nordihydroguaia-retic acid | Blocks H2O2 production in macrophages in response to phorbol esters and in endothelial cells in response to thrombin | Lipooxigenase inhibitor. Blocks arachidonic acid metabolism | [ |
| SKF525A | Decreases superoxide and H2O2 production in endothelial cells | Cytochrome P450 inhibitor | [ |
| Metformin | Scavenges hydroxyl radicals but not superoxide. Could also inhibit PMA and Ang II-dependent ROS production from NADPH oxidase. However, this is likely to be due to inhibition of PKC activity | Antihyperglycemic agent. PKC inhibitor | [ |
| Sildenafil-citrate | Inhibitor of endothelial superoxide production and gp91phox expression | Inhibits phosphodiesterase type 5. Nonselective and in direct inhibitor for NADPH oxidase isoforms. Have been shown to influence immune system due to changes in gp91phox expression | [ |
| Bilirubin | Inhibitor of superoxide production. No effect on Nox2, p22phox and p47phox but may reduce p47phox phosphorylation | ROS scavenger | [ |
| Minocycline | Downregulates p67phox expression. Inhibitor of superoxide generation in microglia and dopaminergic neurons in response to stimuli such as thrombin | Antibiotic | [ |
| Perhexiline | Inhibits superoxide production in intact neutrophils stimulated by fMLP or PMA. Mechanism unknown | Efficient antianginal agent that blocks carnitine-palmitoyl-transferase | [ |
| Roxithromycin | Inhibits superoxide generated by intact neutrophils activated by fMPL or PMA but not by cell lysates. No effect on PKC-dependent phosphorylation. May inhibit translocation of p47phox and/or p67phox | Macrolide antibiotic. Inhibit RNA-dependent protein synthesis. Efficient in blocking cytochrome P450 | [ |
| Taurine chloramines | Inhibits translocation of p47phox and p67phox to the membrane. Also inhibits phosphorylation of p47phox. Reversible inhibition of PMA-dependent superoxide anion production in human neutrophils | Blocks inducible NOS in alveolar macrophages | [ |
| Resveratrol | Reduces superoxide generation in intact macrophages and homogenates. Does not scavenge superoxide in cell-free systems | Inhibitor of PKC | [ |
| Curcurmin | Reduces superoxide production in intact macrophages and homogenates. Does not scavenge superoxide in cell-free systems | Irreversible inhibitor of thioredoxin reductase via alkylation of cysteine residues | [ |
| Nitrolinoleate | Nitrated lipid which blocks PMA- and FMLP-dependent superoxide generation and degranulation in human neutrophils by enhancing cAMP but not cGMP levels | Also linked with increasing cAMP vasorelaxation | [ |
| Mycophenolate acid | Fungal derivative that blocks endothelial and neutrophil-derived superoxide by reducing Rac levels. Does not alter mRNA levels of Nox2, Nox4, and p47phox | Efficient inhibitor of inosine monophosphate dehydrogenase associated with purine synthesis in B and T lymphocytes | [ |
| GK-136901 | Well known NOX1 and NOX4 oxidase inhibitor. Unknown mechanism, but structural similarity with NADPH suggests that it may act as a competitive substrate inhibitor of this enzyme | None | [ |
| ML171 | Phenothiazine compound with selectivity for NOX1 oxidase (IC50 of 0.25 | None | [ |
| Mastoparan | Inhibits superoxide production by neutrophil lysates most likely via interaction with N-terminal of p67phox | An amphiphilic cationic tetradecapeptide isolated from wasp venom. Has affinity towards SH3 domains. Also interact with G-proteins | [ |
| Ghrelin | Blocks superoxide production by thoracic aorta most probably via release of NO. Does not scavenge superoxide | Capable of releasing growth hormone releasing peptide. Stimulates gastric acid secretion | [ |
| Alpha tocopherol | Inhibitor of p67phox-p47phox translocation and p47phox phosphorylation in monocytes, neutrophils and microglial cells. This effect is likely to be due to PKC inhibition | ROS scavenger | [ |
| Benzylisothiocyanate | Concentration-dependent. Inhibits TPA-induced superoxide production in a human leukemia cell line. Does not affect PKC activity and p47phox translocation. Mechanism may involve covalent cysteine modification of the NADPH oxidase | May inhibit NO, PGE2 and TNF- | [ |
| Probucol | Known to reduce superoxide production in rabbit aorta, by down-regulation of p22phox | Free radical scavenger | [ |
| Nox2ds-tat | Oxidase assembly inhibitor: inhibits association of NOX2 subunit with p47phox. Does not scavenge O2 −• generated by cell-free systems | None | [ |
| VAS3947 | Triazolopyrimidine that decreased ROS production in several cell lines with low micro molar efficiency, irrespective of the specific isoforms expressed; showed no inhibitory effects against xanthine oxidase-derived ROS or eNOS activity | None | [ |
Adapted from [125, 216].
eNOS: endothelial nitric oxide synthase; IC50: half-maximal inhibitory concentration; Nox: NADPH oxidase; O2 −•: superoxide; ROS: reactive oxygen species; SH3: Src homology 3; DPI: diphenyleneiodonium chloride; AEBSF: 4-(2-aminoethyl)-benzenesulfonyl fluoride; S178341: 4-dimethyl-2,3,5,6-triiodobenzene; VAS-2870: 3-benzyl-7-(2-benzoxazolyl) thio-1,2,3-triazolo (4,5-d) pyrimidine; SKF 525A: 2-diethylaminoethyl 2:2–diphenylvalerate hydrochloride.